CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Endotoxin (LPS)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00954824
NCT00954824N/ACompleted
CompareCT.gov

Inflammation and the Metabolic Syndrome in Humans

University of Pennsylvania·interventional·Posted Aug 7, 2009·Updated Mar 30, 2017

In Brief

A clinical study evaluating Endotoxin (LPS) for Metabolic Syndrome X. Completed, enrolled 50 participants across 1 site.

Detailed Summary

People who are overweight are at increased risk of heart disease. Being overweight and having heart disease are linked in that both involve inflammation. Inflammation refers to the body's first line of defense against infection and injury. Metabolic changes in cholesterol, triglycerides (fat in the blood) and sugar in the blood caused by inflammation are similar to that in some people who are overweight. The investigators wish to examine the effects of inflammation on these metabolic changes that may lead to heart disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome X
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2009
Enrollment StartAug 1, 2003
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.9 years ago

Interventions

Endotoxin (LPS)biological

Single administration low-dose (3 ng/kg) endotoxin (LPS).